Which statement describes the role of amiodarone in tachyarrhythmias with structural heart disease?

• A. It often worsens hemodynamics.
• B. It offers safer hemodynamics compared with some alternatives.
• C. It is never used in structural heart disease.
• D. It has the shortest half-life among antiarrhythmics.

Answer: (B)

In tachyarrhythmias with structural heart disease, the priority is to control the rhythm without making the heart’s output worse. Amiodarone fits this well because it can suppress a broad range of atrial and ventricular arrhythmias while causing relatively little negative inotropy or blood pressure drop. This means it often preserves hemodynamics better than many other antiarrhythmics, which is especially important when the heart is already damaged. That safer hemodynamic profile makes it a preferred option in patients with structural heart disease who need rhythm control. It’s true that amiodarone can have long-term toxicities and a very long half-life, but those issues pertain to chronic exposure rather than the immediate hemodynamic tolerance that matters in this setting. The other statements don’t fit: it isn’t universally worsening hemodynamics; it is used in structural heart disease; and it does not have the shortest half-life.